Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Net Cash Flow: 2009-2025

Historic Net Cash Flow for Northwest Biotherapeutics (NWBO) over the last 17 years, with Sep 2025 value amounting to -$2.8 million.

  • Northwest Biotherapeutics' Net Cash Flow fell 188.70% to -$2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $513,000, marking a year-over-year increase of 366.36%. This contributed to the annual value of -$1.2 million for FY2024, which is 71.13% up from last year.
  • Northwest Biotherapeutics' Net Cash Flow amounted to -$2.8 million in Q3 2025, which was down 152.20% from $5.5 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Net Cash Flow ranged from a high of $10.9 million in Q4 2021 and a low of -$9.1 million during Q1 2022.
  • In the last 3 years, Northwest Biotherapeutics' Net Cash Flow had a median value of $10,000 in 2023 and averaged -$66,545.
  • Its Net Cash Flow has fluctuated over the past 5 years, first soared by 2,662.04% in 2023, then crashed by 5,700.00% in 2024.
  • Quarterly analysis of 5 years shows Northwest Biotherapeutics' Net Cash Flow stood at $10.9 million in 2021, then slumped by 96.85% to $342,000 in 2022, then slumped by 965.79% to -$3.0 million in 2023, then slumped by 45.80% to -$4.3 million in 2024, then slumped by 188.70% to -$2.8 million in 2025.
  • Its Net Cash Flow stands at -$2.8 million for Q3 2025, versus $5.5 million for Q2 2025 and $2.2 million for Q1 2025.